You are here: Home: Meet The Professors Vol. 2 2004: Case 3: Select publications
 |
| Select publications |
 |
Arpino G etal. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6(3):R149-56. Abstract
Bast RC Jr et al. 2000 update of colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19(6):1865-78.Abstract
Chow CE Metastatic lobular breast cancer presenting with malignant ascites: case report al. and review of literature. Breast J 2003;9(5):414-6. Abstract
Dowsett M et al. Analysis of time to recurrence combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003; . Abstract 4
Ferlicot S etal. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 2004;40(3):336-41. Abstract
Gion M etal. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Cancer J 2001;7(3):181-90. Abstract
Howell A etal. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat 2003;82(3):215-22. Abstract
Howell A etal. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract
Howell A etal. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmeno -pausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract
Kurebayashi Jetal. Significance of serum carcinoembryonic antigen and CA 15-3 in monitor -ing advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study. Breast Cancer 2003;10(1):38-44. Abstract
Li CI et al. Risk of mortality by histologic type of breast years. Arch Intern Med 2003;163(18):2149-53. Abstract
Locker GY et al. The time course of bone fractures observed in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2003; . Abstract 98
Mackey JR, VennerPM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 1996;6(2):474-80. Abstract.
Mauriac L etal. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract
Molina R etal. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res 2003;23(2A):1043-50. Abstract
Molina R etal. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 2003;23(2A):1035-41. Abstract
Osborne CKetal. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract
Partridge AHetal. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21(4):602-6. Abstract
Ring AE etal. Identification of putative cancer cells from the blood of patients with breast cancer: a comparison of threetechniques. Breast Cancer Res Treat 2003; . Abstract 423
Vergote I et. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer ResTreat 2003;79(2):207-11.Abstract
Vergote I, RobertsonJF. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Br J Cancer 2004;90(Suppl 1):11-4. Abstract
|
